This episode features an interview with Marci English, Vice President and Head of BioPharma Development at Astellas Pharma, about the recent FDA approval of the company’s drug Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause.
Hormone replacement therapy (HRT) has been the conventional treatment for menopause-associated vasomotor symptoms, otherwise known as hot flashes and night sweats; however, not all women can receive hormone therapies. Apart from HRT, treatment options have been limited for the vasomotor symptoms of menopause and therefore, the approval of Veozah addresses a significant unmet need in the space.
Hear more about Veozah, including its mechanism of action and the pathways to its approval.
Read the full article here: Veozah (Fezolinetant) Is a New Type of Drug for Menopausal Hot Flashes
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.